The forward P/E of 28.49 and PEG of 1.66 suggest the market still assigns a growth premium, yet a PEG above 1.5 leaves little margin of safety if the 18% EPS growth guided for 2026 slips. Compared with CONMED at roughly 34 P/E and 12 EV/EBITDA, LMAT trades at a similar earnings multiple but a meaningfully higher enterprise multiple, which may reflect its net cash position and higher gross margins rather than superior growth. Investors should monitor whether Q4 EPS delivers within the $0.70 to $0.75 guidance range, since failure would likely compress the multiple.

The sustained gross margin near 72% suggests pricing power in niche open vascular categories remains intact, consistent with limited competition from larger endovascular-focused rivals. The compression in operating margin, however, appears driven by a sales force build-out that has raised SG&A faster than revenue, which may indicate the operating leverage thesis is being deferred rather than broken. Net margin of 22.1% is still well above most peers, but the trend warrants monitoring as wage inflation for specialized representatives continues.

The depressed return metrics appear largely a function of a growing equity base, which rose from $331M to $432M over eight quarters, rather than deteriorating operations alone. Returns on invested capital near 2 to 3% suggest the incremental capital deployed into warehouse expansion and sales infrastructure has not yet produced proportional earnings. Investors should assess whether these investments mature into higher returns over the next several reporting periods.

The jump in total debt to roughly $189M materially changed the capital structure, though the D/EBITDA of 9.18 is elevated and warrants closer scrutiny of refinancing timing and covenant terms, which are not disclosed in the supplied data. Coverage has remained in the 13 to 18 times range across recent quarters, which suggests current earnings absorb interest costs without strain. The key question is whether the EBITDA base holds if sequential revenue weakness persists.

The high current ratio is driven by a large inventory and receivables base rather than a pile of cash, so liquidity under stress depends on the collectability of receivables and the saleability of biological tissue inventory. The quick ratio remaining above 12 suggests limited dependence on inventory, which is a favorable structural feature. Under a severe demand shock, the company would likely rely on operating cash flow to service debt rather than its balance sheet cash.

Inventory days of 48 and receivable days near 0.10 (on an asset turnover basis) suggest the working capital profile is dominated by payables rather than customer collections. A DPO well above the DIO and DSO implies LMAT is effectively financed by its suppliers, which may be sustainable but is not guaranteed to persist. Analysts should verify the composition of payables and whether the swings between 268 and 391 days reflect structural terms or quarter-end timing.